Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) has received Type C meeting guidance from the FDA regarding the design of its Phase 2b clinical trial. The FDA provided preliminary agreement on Lipella’s overall trial design, including objectives, safety monitoring, control group monitoring, the dosing protocol, the primary efficacy endpoint, and sample size considerations. The… [Read More]
May 21, 2024
Inside Look at Retail: Mixed Reports Across Multiple Industries as Earnings Season Slows – TGT, AZO, LOW, M
Despite headline news amping up for the big NVIDA Corp (NVDA) announcement tomorrow after the close, there have been some notable retail announcements contributing to this week’s tail end of earnings season. A good mix of retail companies have reported this week that have given investors an insight into the health of certain industries within… [Read More]
Surgical robotics company, SS Innovations International, Inc. (SSII) has announced a milestone for robotic cardiac surgery as its SSi Mantra Surgical Robotic System has surpassed its 100th cardiac surgery. The company who is dedicated to making world class robotic surgery affordable and accessible, globally implements the world’s only comprehensive robotic cardiac surgery program. Additionally, its… [Read More]
May 21, 2024
Prism Stocks making the biggest moves premarket: Macy’s, Lowe’s, Peloton, Zoom Video and more
Here are the top companies capturing attention in premarket trading: Macy’s proved its mettle by gaining 3% on the back of sterling first-quarter earnings results and an upgraded outlook for the full year, thanks to a successful turnaround strategy. Lowe’s boosted its stock by over 2% as its first-quarter reports surpassed market expectations, posting $3.06… [Read More]
Shares in biotechnology company, NKGen Biotech (Nasdaq: NKGN) soared more than 75% in morning trading on Monday after the company announced that its lead candidate SNK01 has received Safety Review Committee clearance to progress into Phase 2 clinical development. The company is evaluating SNK01, a novel cell-based, patient-specific expanded autologous natural killer cell, immunotherapeutic drug… [Read More]
May 20, 2024
As AI Utilization in Security Screening Broadens, PRISM AI Emerger Evolv (EVLV) is Taking Stake
While earnings season is wrapping up, there is still one name on everyone’s watchlist, NVIDIA Corporation (NVDA). Its announcement should provide color on the AI landscape in addition to its partnerships that may boost other names within the space. PRISM MarketView highlights some emerging names with a focus on AI in its PRISM Emerging NextGen… [Read More]
May 20, 2024
BranchOut Food Achieves Record First Quarter
Leading food technology company, BranchOut Food Inc. (Nasdaq: BOF), has reported record financial results for the first quarter ending March 31, 2024. The company achieved revenue growth of 1,407%, year over year, reaching $1.47 million. Additionally, BranchOut Food achieved a gross margin of 19% in Q1 2024, a significant improvement from -3% in Q1 2023…. [Read More]
MIRA Pharmaceuticals (Nasdaq: MIRA) is advancing closer to clinical development of what could potentially be the first at-home ketamine-based treatment for post-traumatic stress disorder (PTSD). MIRA is evaluating Ketamir-2, its differentiated oral ketamine analog, for the treatment of severe PTSD, along with other mental health disorders and neuropathic pain indications. The company’s share price soared… [Read More]
May 20, 2024
Prism Stocks making the biggest moves midday: Hims & Hers Health, Norwegian Cruise Line, Target and more
Unveil the companies that are making waves in the midday trading scene: Hims & Hers Health — Their stocks skyrocketed by over 30% subsequent to the announcement of the telehealth company’s new availability of compounded GLP-1 injections, an expansion of their weight loss program initiated in December. Wix.com — This web development firm saw a… [Read More]
Here’s a glimpse at the movers and shakers in the market before the opening bell. Apple — The high-tech giant’s shares took a slight dip of under 1% after Reuters broke the news that Apple is slashing prices on iPhones in China. Micron Technology — An upgrade from Morgan Stanley from underweight to equal weight… [Read More]
May 18, 2024
What’s Next in the Great GLP-1 Race?
Roche Holding (RHHBY) joined the race to commercialize its own GLP-1 (glucagon-like peptide-1) receptor agonist drug this week, announcing that its dual-agonist asset, CT-388, had achieved statistically significant weight loss in people with obesity in an early stage trial. At week 24 of treatment, 45% of participants achieved weight loss of approximately 20% of their… [Read More]